4-aminobenzoic acid has been researched along with Ovarian Neoplasms in 6 studies
para-Aminobenzoates: Benzoic acids, salts, or esters that contain an amino group attached to carbon number 4 of the benzene ring structure.
4-aminobenzoate : An aromatic amino-acid anion that is the conjugate base of 4-aminobenzoic acid.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A combination of aprotinin with tranexamic acid may be effective in preventing or delaying rebleeding after rupture of an intracerebral aneurysm; the addition of aprotinin seems to decrease the incidence of delayed cerebral vasospasm and ischaemic complications which are sometimes noted when tranexamic acid alone is used." | 4.77 | Clinical application of inhibitors of fibrinolysis. ( Verstraete, M, 1985) |
| "Ovarian cancer is the leading cause of death due to gynecologic malignancies worldwide." | 2.53 | Nitric oxide signaling in human ovarian cancer: A potential therapeutic target. ( El-Sehemy, A; Fu, Y; Postovit, LM, 2016) |
| "Ovarian cancer is a gynecological cancer that has the highest mortality rate and is often resistant to conventional treatments." | 1.56 | Combination of metformin and RG7388 enhances inhibition of growth and induction of apoptosis of ovarian cancer cells through the PI3K/AKT/mTOR pathway. ( Cui, Y; Rong, F; Zhou, J, 2020) |
| "Ovarian cancer is the fifth leading cause of cancer-related female deaths." | 1.43 | Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer. ( Edmondson, RJ; Lunec, J; Zanjirband, M, 2016) |
| "In patients with ovarian cancer, PAI-1 mRNA expression in tumor tissues was positively correlated with poor prognosis." | 1.42 | Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer. ( Dan, T; Ichimura, A; Ishibashi, M; Kitatani, K; Mashiko, S; Miyata, T; Nagase, S; Shigeta, S; Toyoshima, M; Usui, T; Yaegashi, N, 2015) |
| "The rapid proliferation of cancer cells mandates a high protein turnover." | 1.35 | Nitrosative stress-induced s-glutathionylation of protein disulfide isomerase leads to activation of the unfolded protein response. ( Bowers, RR; He, L; Hutchens, S; Manevich, Y; Tew, KD; Townsend, DM; Xiong, Y, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, Y | 1 |
| Zhou, J | 1 |
| Rong, F | 1 |
| Mashiko, S | 1 |
| Kitatani, K | 1 |
| Toyoshima, M | 1 |
| Ichimura, A | 1 |
| Dan, T | 1 |
| Usui, T | 1 |
| Ishibashi, M | 1 |
| Shigeta, S | 1 |
| Nagase, S | 1 |
| Miyata, T | 1 |
| Yaegashi, N | 1 |
| El-Sehemy, A | 1 |
| Postovit, LM | 1 |
| Fu, Y | 1 |
| Zanjirband, M | 1 |
| Edmondson, RJ | 1 |
| Lunec, J | 1 |
| Townsend, DM | 1 |
| Manevich, Y | 1 |
| He, L | 1 |
| Xiong, Y | 1 |
| Bowers, RR | 1 |
| Hutchens, S | 1 |
| Tew, KD | 1 |
| Verstraete, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy in Controlling Bleeding Post-coronary Bypass Surgery Using Combination of Local Application of Tranexamic Acid and Intravenous Tranexamic Compared to Intravenous Tranexamic Acid Alone. A Randomized Controlled Trial[NCT01600599] | 40 participants (Actual) | Interventional | 2011-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for 4-aminobenzoic acid and Ovarian Neoplasms
| Article | Year |
|---|---|
Nitric oxide signaling in human ovarian cancer: A potential therapeutic target.
Topics: Antineoplastic Agents; Apoptosis; Azo Compounds; Biomarkers, Tumor; Drug Resistance, Neoplasm; Femal | 2016 |
Clinical application of inhibitors of fibrinolysis.
Topics: 4-Aminobenzoic Acid; Aminocaproic Acid; Angioedema; Antifibrinolytic Agents; Aprotinin; Blood Preser | 1985 |
4 other studies available for 4-aminobenzoic acid and Ovarian Neoplasms
| Article | Year |
|---|---|
Combination of metformin and RG7388 enhances inhibition of growth and induction of apoptosis of ovarian cancer cells through the PI3K/AKT/mTOR pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Prolifera | 2020 |
Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Gene | 2015 |
Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; DNA Repair; Female; Gene Expressi | 2016 |
Nitrosative stress-induced s-glutathionylation of protein disulfide isomerase leads to activation of the unfolded protein response.
Topics: 4-Aminobenzoic Acid; Amino Acid Sequence; Azo Compounds; Catalytic Domain; Cell Line, Tumor; Cystein | 2009 |